The Fed could sound slightly more upbeat about the economy — and that could be enough to reinforce Wall Street's growing view.
Jim Cramer gives his take on various caller stocks at lightning speed, and says these two stocks are about to head downhill.
The final week of July is guaranteed to be one of the busiest of summer. The coming week is packed with potential market movers.
CNBC's Simon Hobbs and the Options Action traders discuss the stocks they'll be watching next week.
United Therapeutics' Martine Rothblatt says investors with vision should get into her biotech firm now, before it grows to Google-like proportions.
A number of America's largest companies are slashing funding to the GOP convention, from hundreds of thousands of dollars in 2012 to zero in 2016.
Goldman Sachs chief U.S. equity strategist David Kostin is expecting a pullback and a range-bound market for the next two years.
CNBC's Meg Tirrell discusses biotech in the bear market and what to expect going forward.
CNBC's Melissa Lee and the Options Action traders discuss the stocks they'll be watching next week.
CNBC's Meg Tirrell looks into the biotech sector and Melissa Lee and the Options Action traders give their takes on whether to hide out in the healthcare sector.
These stocks to buy on a pullback are the least exposed to a potential European economic crisis, according to Morgan Stanley.
Amgen Chairman and CEO Robert Bradway, provides insight to product innovation, the impact from the political cycle and the outlook for M&A.
Discussing the current state of valuation in the markets with Chad Morganlander, Stifel Portfolio Manager, and Jack Ablin, BMO Private Bank Executive VP & Chief Investment Officer.
Amgen said Wednesday that it has seen positive results for the chronic-migraine prevention drug it has been developing with Novartis.
Michael Farr, Farr Miller & Washington, and Kevin Norris, Univest Wealth Management President, discuss their summer market outlooks and give their picks.
Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback.
The biotech sector has been sliding, but a turnaround could be afoot. Chad Morganlander of Stifel Nicolaus and Craig Johnson of Piper Jaffray discuss with Brian Sullivan.
Amgen is working on a drug to lower the risk of heart attack, reports CNBC's Meg Tirrell.
Nutanix is the biggest tech name on file for an IPO. While investors wait, its co-founder is bulking up a new company — ThoughtSpot.
A rare and previously unknown variation in some people's genes substantially reduces their heart attack risk, the Icelandic researchers said.